Dishman Pharmaceuticals and Chemicals has registered strong growth in bottom line during the second quarter ended September 2016 due to higher sales and lower interest burden. Its consolidated net profit increased by 97.2 per cent to Rs.54.68 crore from Rs.27.73 crore in the corresponding period of last year. Its net sales moved up 14.5 per cent to Rs.426.94 crore from Rs.372.89 crore. EPS increased to Rs.3.39 from Rs.1.72 in the last period.

The sales from CRAMS improved by 20.1 per cent to Rs.323.99 crore from Rs.269.67 crore. The sales of bulk drugs, intermediates, quats, speciality chemicals, vitamin D3 analogue and traded goods declined slightly by 0.3 per cent to Rs.103 crore. Its interest cost declined by 27.5 per cent to Rs.18.90 crore from Rs.22.46 crore.

After the announcement of financial results, Dishman scrip moved up sharply by over 6 per cent to Rs.242.65 on BSE. The scrip started upward movements after March 2016 and reached at yearly highest level at Rs.267.95 on September 30, 2016.

For the first half ended September 2016, Dishman's consolidated net sales improved by 2.6 per cent to Rs.793 crore from Rs.772 crore in the same period of last year. CRAMS sales increased by 11.5 per cent to Rs.582 crore from Rs.522 crore. However, the sales of other products declined by 16 per cent to Rs.211 crore. Its net profit went up by 47.6 per cent to Rs.100 crore from Rs.68 crore. Its EPS improved to Rs.6.21 from Rs.4.20 in the last period. Its interest cost declined by 28.5 per cent to Rs.41 crore from Rs.58 crore.